ATP6V0A1 and hepatitis C virus infection: We found that daclatasvir (Dac), a clinical used drug to treat chronic genotype I and III hepatitis C virus (HCV) infection23, was able to bind to ATP6V0A1 protein (Fig. 9A and Supplementary Fig. 25A, B).